Schering-Plough's Q2 income down

Jul 23, 2008 ( Shah's finance Datamonitor via COMTEX) -- SGP Quote Chart News PowerRating -- Schering-Plough has posted a net income of $398 million for the second quarter of 2008, compared with $517 million for the same quarter in 2007.

The company attributed the lower second quarter earnings to the acquisition of biotech group Organon BioSciences.

The company posted net sales of $4.9 billion in the second quarter of 2008, up 55%, compared to $3.18 billion in the second quarter of 2007.
Fred Hassan, chairman and CEO of Schering-Plough, said: "We are very pleased to see another quarter of strong performance and broad-based growth for our company. Through the action agenda we launched in 2003, we were determined to diversify our company and to build a deep Phase III pipeline.
"Today, we are succeeding on both fronts. Our Phase III pipeline is now the strongest in our company's history, and the $16 billion acquisition of Organon BioSciences in November 2007 has already met its accretion target for 2008."

Shah downgraded the company's share sell saying technically in weekly frame chart price recovered from down and met the value line and ready to fall again. He wrote also all the indicators in both type of charts daily frame and weekly frame are negative and intends to move down more. He made his Target price at $ 18.00.

www.stockdselse.blogspot.com

SSL International says Q1 trading in line with its expectations

LONDON, Jul 24, 2008 ( Shah's financial ) -- SLSLF Quote Chart News PowerRating -- SSL International Plc. said its first quarter trading is in line with expectations with good underlying revenue growth, beneficial exchange rate movement and a strong balance sheet.
"Durex and Scholl, continue to make good progress, driving us towards our target of growing operating profit by at least 10 percent again this year," said chairman Gerald Corbett.
In a trading statement, the consumer products manufacturer said its gross margin is being maintained despite input cost inflation and added that it continues to expect at least a constant gross margin on a full-year basis.

Shah upgrded the stock as BUY maaking target price £500 in his research note.

SGP Upgraded by Lehman Brothers as "Overweight"

Schering-Plough opened at $21.8. So far today the stock has hit a low of $21.57 and a high of $21.95. SGP is now trading at $21.90, up 0.52 (2.43%). After hitting a one-year high of $33.40 in October, the stock hit a one-year low of $13.83 in April. SGP shares are rising this morning after an analyst at Lehman Brothers upgraded the stock to "Overweight" from "Equal weight," and lifted his price target to $27 per share from $22. The analyst added that he thinks SGP will see improving sales of its cholesterol drugs, and should benefit from a limited amount of expiring drug patents over the next five years. Technical indicators for SGP are bullish and steady, while S&P gives the stock a neutral 3 Stars (out of 5) Hold rating. If you’re looking for a hedged play on this stock, consider a November bull-put credit spread below the $17.50 range. SGP hasn't been below 17.50 since April. The stock could lose up to 20.0% before this trade runs into trouble.

DSE Rose a Few Chances

In a note analyst Shah wrote that some compaies of DSE made a chance for rittle investors. He upgraded some companies on the besis of technical. He rated AB Bank, BEXIMCO, KYA COS, ACI, AMBEEFRMA, AMCL PRAN, FUWAN FOOD and PADMA CEMENT as BUY for the next 10 trading days.
He comented these are potential trade that can be opened on the following sunday.